- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05161182
Westlake N-of-1 Trials for Macronutrient Intake 2 ( WE-MACNUTR 2)
Westlake Personalized Nutrition Intervention Study: N-of-1 Trials for Dietary Macronutrient Intake 2
Diet and nutrition are key to maintain human health. Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR) trial investigates individualized postprandial glycemic responses to different proportions of dietary fat and carbohydrates intake using an n-of-1 experimental study design. The experimental diets are isocaloric high fat, low carbohydrate (HF-LC) or low fat, high carbohydrate (LF-HC). With standardized intervention and strictly controlled eating behaviors, the WE-MACNUTR study identifies specific HC-responders and HF-responders in terms of postprandial glucose response.
This is a follow-up study offered to participants who have completed the WE-MACNUTR study in 2019. Volunteers will be asked to participate in four 5-d periods while wearing glucose monitors (Abbott Freestyle Libre) with the following experimental sequence: 1) a washout diet, 2) HF-LC or LC-HF diet, 3) a washout diet, 4) HF-LC or LC-HF diet. The experimental diet will be randomly assigned. Participants will be asked to provide a fasted blood sample and to collect fecal, urine and saliva samples at each visits.
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is a two arm dietary intervention study. Participants will be recruited from the WE-MACNUTR study based on the defined inclusion and exclusion criteria. The study duration will last up to 21 days.
Volunteers will be asked to participate in four 5-day periods while wearing glucose monitors (Abbott Freestyle Libre) with the following experimental sequence: 1) a washout diet, 2) HF-LC or LC-HF diet, 3) a washout diet, 4) HF-LC or LC-HF diet. The experimental diet will be randomly assigned.
Participants will enter the study on a usual (washout) diet and will have a 5-day run in period for baseline data collection. Participants will be asked to follow dietary guidance and consumed a healthy and balanced diet during this period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310024
- Westlake University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants have completed WE-MACNUTR trial in 2019
- Participants have no traveling plans within 1 months
- Participants are able and willing to comply with the study protocol and provide informed consent
Exclusion Criteria:
- Refuse or are unable to provide informed consent to participate in the study
- Have long-term gastrointestinal diseases and take daily relevant medications
- Have taken antibiotics in the last 2 weeks
- Have type 2 diabetes and are taking medications or other treatments
- Have chronic or acute liver disease and are taking medications or other treatments
- Have cardiovascular diseases and are taking medications or other treatments
- Have kidney disease and are taking medications
- Suffer from chronic anxiety or depression, or other critical neuronal disorder and/or history of relevant medication
- Are pregnant or lactating, or are planning to be pregnant in the next 3 months
- Diagnosed with an eating disorder (e.g. anorexia nervosa or bulimia nervosa)
- Are vegan, or unwilling to consume foods provided in the study
- Have history of alcohol or drug addiction, or smoke above 15 cigarettes per day
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High fat, low carbohydrate diet
|
Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
Other Names:
|
|
Experimental: Low fat, high carbohydrate diet
|
Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood glucose profiling
Time Frame: 20 days
|
Real-time blood glucose fluctuations will be recorded by CGM.
|
20 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Urines untargeted metabolomics profiling
Time Frame: Day 6, day 11 day 16 and day 21 of the study
|
Urine metabolite extracts will be analysed by performing liquid chromatography/quadrupole time-of-flight mass spectrometry (LC/Q-TOF/MS).
Compound will be identified by retention time and relative amount.
|
Day 6, day 11 day 16 and day 21 of the study
|
|
Fecal targeted metabolomics profiling
Time Frame: Day 6, day 11 day 16 and day 21 of the study
|
Fecal metabolite extracts will be analysed by performing liquid chromatography/quadrupole time-of-flight mass spectrometry (LC/Q-TOF/MS).
Metabolites, L-alanine for example, will be identified in μmol/L.
|
Day 6, day 11 day 16 and day 21 of the study
|
|
Microbiome taxonomic profiling
Time Frame: Day 6, day 11 day 16 and day 21 of the study
|
Stool samples will be collected on day 6, day 11 day 16 and day 21 of the study.
Shotgun metagenomic sequencing will be performed in stool samples.
The taxonomic profiling and the organisms' relative abundance will be quantified using MetaPhlAn.
|
Day 6, day 11 day 16 and day 21 of the study
|
|
Serum metabolomics profile
Time Frame: Day 6, day 11 day 16 and day 21 of the study
|
Venous blood samples will be collected at fasting in the morning on day 6, day 11 day 16 and day 21 of the study.
The liquid chromatography/mass spectrometry (LC/MS) method with targeted metabolomics will be performed in blood serum.
Compound (amino acids, fatty acids and bile acids) will be identified by retention time and relative amount.
|
Day 6, day 11 day 16 and day 21 of the study
|
|
Lipid metabolism
Time Frame: Day 6, day 11 day 16 and day 21 of the study
|
Triglyceride, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, apolipoprotein A1 and apolipoprotein B will be analyzed at all visits of the study.
|
Day 6, day 11 day 16 and day 21 of the study
|
|
Body composition
Time Frame: Day 5 of the study
|
Body composition (fat mass, lean mass in kg ) will be assessed by bioelectrical impedance analysis.
|
Day 5 of the study
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20211011ZJS001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postprandial Hyperglycemia
-
San Diego State UniversityCompletedPostprandial Hyperglycemia | Postprandial Glycemic Response | Postprandial InsulinUnited States
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
San Diego State UniversityCompletedPostprandial Hyperglycemia | Postprandial InsulinUnited States
-
Clinica Universidad de Navarra, Universidad de...CompletedLipid Profile | Hyperglycemia, Postprandial | Feeding Behaviors | Antioxidant | PostprandialSpain
-
Harokopio UniversityNational and Kapodistrian University of AthensCompleted
-
University of SharjahCompletedPostprandial HyperglycemiaUnited Arab Emirates
-
Egas Moniz - Cooperativa de Ensino Superior, CRLCompletedHyperglycemia, PostprandialPortugal
-
University of BergenCompleted
-
Franklin Pierce UniversityTerminatedHyperglycemia, PostprandialUnited States
-
San Diego State UniversityCompleted
Clinical Trials on High fat, low carbohydrate diet
-
UCSF Benioff Children's Hospital OaklandNational Cattlemen's Beef AssociationCompletedHealthy | Cardiovascular Disease | Atherogenic DyslipidemiaUnited States
-
Haukeland University HospitalUniversity of BergenCompleted
-
Vårdcentralen LyckornaCompleted
-
University of NottinghamMars, Inc.Completed
-
University of ArkansasCompletedDiabetes Mellitus | HypertriglyceridemiaUnited States
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Chinese Academy of SciencesCompletedHealthy and Overweight/ Obesity MalesChina
-
Westlake UniversityCompletedPostprandial Hyperglycemia | Metabolic Disorder, GlucoseChina
-
Brigham and Women's HospitalCompletedCardiovascular Diseases | OverweightUnited States
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)RecruitingAlzheimer Disease | Mild Cognitive ImpairmentUnited States